Argus
•
Nov 06, 2026
AbbVie Inc.: Raising target price to $320
Summary
AbbVie Inc., a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
SMID November 2026 Pick List
Nov 06, 2026
•
CARR, CTVA, FLUT, AMCR, F, KHC, LVS, RIVN, O, BR, Q, CRWV, CTSH, LPLA, HONA, ON, PYPL, ZBH, RMD, BKR, OTIS, HSY, WSO, EXE, PCG, INVH, EIX, ALB, CPNG, MDLN
Analyst Report: Altria Group, Inc.
Nov 06, 2026
•
MO
Analyst Report: 3M Company
Nov 04, 2026
•
MMM
Analyst Report: Pfizer Inc
Nov 04, 2026
•
PFE
Analyst Report: 3M Co
Nov 04, 2026
•
MMM
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
